Biofrontera (BFRI) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BFRI shares.
View BFRI analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month target prices for Biofrontera's stock. Their BFRI share price forecasts range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,405.4% from the stock's current price.
View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts.

Biofrontera's stock was trading at $0.9166 at the beginning of the year. Since then, BFRI stock has decreased by 49.3% and is now trading at $0.4650.
View the best growth stocks for 2023 here.

Biofrontera saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 270,800 shares, an increase of 12.3% from the April 30th total of 241,200 shares. Based on an average trading volume of 95,100 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.8% of the shares of the company are short sold.
View Biofrontera's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our BFRI earnings forecast.

Biofrontera Inc. (NASDAQ:BFRI) released its earnings results on Monday, March, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.01. The company earned $10.14 million during the quarter, compared to analysts' expectations of $10.32 million. Biofrontera had a negative trailing twelve-month return on equity of 109.94% and a negative net margin of 49.46%.

Biofrontera issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $35.84M-, compared to the consensus revenue estimate of $36.50 million.

(BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

Biofrontera trades on the NASDAQ under the ticker symbol "BFRI."

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BFRI stock can currently be purchased for approximately $0.47.

Biofrontera (NASDAQ:BFRI) has a market capitalization of $12.42 million and generates $28.67 million in revenue each year. The company earns $-640,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.

The official website for the company is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at us-ir@biofrontera.com.